118 related articles for article (PubMed ID: 17428314)
1. Inhibitory effects of estrogen receptor beta on specific hormone-responsive gene expression and association with disease outcome in primary breast cancer.
Lin CY; Ström A; Li Kong S; Kietz S; Thomsen JS; Tee JB; Vega VB; Miller LD; Smeds J; Bergh J; Gustafsson JA; Liu ET
Breast Cancer Res; 2007; 9(2):R25. PubMed ID: 17428314
[TBL] [Abstract][Full Text] [Related]
2. Estrogen receptor-beta and breast cancer: translating biology into clinical practice.
Leung YK; Lee MT; Lam HM; Tarapore P; Ho SM
Steroids; 2012 Jun; 77(7):727-37. PubMed ID: 22465878
[TBL] [Abstract][Full Text] [Related]
3. A mixture of
Song J; Han S; Choi S; Lee J; Jeong Y; Lee HM; Son J; Jeong DY; Yu SS; Lee W
Heliyon; 2024 Jan; 10(2):e24842. PubMed ID: 38312605
[TBL] [Abstract][Full Text] [Related]
4. High Expression of CKS2 Predicts Adverse Outcomes: A Potential Therapeutic Target for Glioma.
Yu K; Ji Y; Liu M; Shen F; Xiong X; Gu L; Lu T; Ye Y; Feng S; He J
Front Immunol; 2022; 13():881453. PubMed ID: 35663965
[TBL] [Abstract][Full Text] [Related]
5. Natural and Synthetic Estrogens in Chronic Inflammation and Breast Cancer.
Maharjan CK; Mo J; Wang L; Kim MC; Wang S; Borcherding N; Vikas P; Zhang W
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008370
[TBL] [Abstract][Full Text] [Related]
6. Estrogen Receptor Beta (ERβ): A Ligand Activated Tumor Suppressor.
Mal R; Magner A; David J; Datta J; Vallabhaneni M; Kassem M; Manouchehri J; Willingham N; Stover D; Vandeusen J; Sardesai S; Williams N; Wesolowski R; Lustberg M; Ganju RK; Ramaswamy B; Cherian MA
Front Oncol; 2020; 10():587386. PubMed ID: 33194742
[TBL] [Abstract][Full Text] [Related]
7. Estrogen Signaling and Its Potential as a Target for Therapy in Ovarian Cancer.
Langdon SP; Herrington CS; Hollis RL; Gourley C
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32580290
[TBL] [Abstract][Full Text] [Related]
8. Insights into the Role of Estrogen Receptor β in Triple-Negative Breast Cancer.
Sellitto A; D'Agostino Y; Alexandrova E; Lamberti J; Pecoraro G; Memoli D; Rocco D; Coviello E; Giurato G; Nassa G; Tarallo R; Weisz A; Rizzo F
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32516978
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis.
Feng Y; Spezia M; Huang S; Yuan C; Zeng Z; Zhang L; Ji X; Liu W; Huang B; Luo W; Liu B; Lei Y; Du S; Vuppalapati A; Luu HH; Haydon RC; He TC; Ren G
Genes Dis; 2018 Jun; 5(2):77-106. PubMed ID: 30258937
[TBL] [Abstract][Full Text] [Related]
10. Selective oestrogen receptor antagonists inhibit oesophageal cancer cell proliferation in vitro.
Al-Khyatt W; Tufarelli C; Khan R; Iftikhar SY
BMC Cancer; 2018 Feb; 18(1):121. PubMed ID: 29390981
[TBL] [Abstract][Full Text] [Related]
11. The nuclear receptor ERβ engages AGO2 in regulation of gene transcription, RNA splicing and RISC loading.
Tarallo R; Giurato G; Bruno G; Ravo M; Rizzo F; Salvati A; Ricciardi L; Marchese G; Cordella A; Rocco T; Gigantino V; Pierri B; Cimmino G; Milanesi L; Ambrosino C; Nyman TA; Nassa G; Weisz A
Genome Biol; 2017 Oct; 18(1):189. PubMed ID: 29017520
[TBL] [Abstract][Full Text] [Related]
12. E
Chang-Lee SN; Hsu HH; Shibu MA; Ho TJ; Tsai CH; Chen MC; Tu CC; Viswanadha VP; Kuo WW; Huang CY
Pathol Oncol Res; 2017 Jul; 23(3):477-485. PubMed ID: 27757837
[TBL] [Abstract][Full Text] [Related]
13. Editor's Highlight: Development of an In vitro Assay Measuring Uterine-Specific Estrogenic Responses for Use in Chemical Safety Assessment.
Miller MM; Alyea RA; LeSommer C; Doheny DL; Rowley SM; Childs KM; Balbuena P; Ross SM; Dong J; Sun B; Andersen MA; Clewell RA
Toxicol Sci; 2016 Nov; 154(1):162-173. PubMed ID: 27503385
[TBL] [Abstract][Full Text] [Related]
14. Triple-negative breast cancer: new perspectives for targeted therapies.
Tomao F; Papa A; Zaccarelli E; Rossi L; Caruso D; Minozzi M; Vici P; Frati L; Tomao S
Onco Targets Ther; 2015; 8():177-93. PubMed ID: 25653541
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of estrogen receptor β in breast and prostate cancer from biological aspects.
Omoto Y; Iwase H
Cancer Sci; 2015 Apr; 106(4):337-43. PubMed ID: 25611678
[TBL] [Abstract][Full Text] [Related]
16. Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer.
Bhola NE; Jansen VM; Bafna S; Giltnane JM; Balko JM; Estrada MV; Meszoely I; Mayer I; Abramson V; Ye F; Sanders M; Dugger TC; Allen EV; Arteaga CL
Cancer Res; 2015 Jan; 75(2):405-14. PubMed ID: 25480943
[TBL] [Abstract][Full Text] [Related]
17. GPER mediates estrogen-induced signaling and proliferation in human breast epithelial cells and normal and malignant breast.
Scaling AL; Prossnitz ER; Hathaway HJ
Horm Cancer; 2014 Jun; 5(3):146-160. PubMed ID: 24718936
[TBL] [Abstract][Full Text] [Related]
18. Estrogen receptor beta as a novel target of androgen receptor action in breast cancer cell lines.
Rizza P; Barone I; Zito D; Giordano F; Lanzino M; De Amicis F; Mauro L; Sisci D; Catalano S; Dahlman Wright K; Gustafsson JA; Andò S
Breast Cancer Res; 2014 Feb; 16(1):R21. PubMed ID: 24552459
[TBL] [Abstract][Full Text] [Related]
19. Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients.
Tessari A; Palmieri D; Di Cosimo S
Pharmgenomics Pers Med; 2013 Dec; 7():1-19. PubMed ID: 24403841
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
